Tallying Late-Stage Licensing Opportunities
Executive Summary
At Windhover's Pharmaceutical Strategic Alliances conference in New York last month, 65% of the audience said by electronic poll that their firms were likely to seek to in-license a late-phase product candidate in the next year. But that's going to be easier said than done. There simply aren't many compounds available for licensing in the US.